IntroductionPregabalin is an antiepileptic drug prescribed as first‐line treatment for chronic neuropathic pain (Finnerup et al., ) mainly acting on the α2δ‐1 calcium channel subunit, which is critical for functional expression of voltage‐gated calcium channels (Field et al., ; Patel and Dickenson, ). Multiple preclinical studies have shown the efficacy of pregabalin alleviating hypernociception associated with neuropathic injuries (Field et al., , ; Nozaki‐Taguchi et al., ; Kremer et al., ). While some of these studies describe complete reversion of neuropathic hypersensitivity, it should be noted that the number of patients needed to treat for 50% pain relief (i.e. patients who need to be treated to obtain one with a 50% of pain relief) is estimated between 6.5 and 9.4 (Finnerup et al., ). This discordance between clinical data and preclinical studies may be related to the measurement of evoked sensitivity in the current preclinical studies. While one of the most prevalent symptoms in chronic neuropathic syndromes is spontaneous pain (96% of the cases (Backonja and Stacey, )), studies estimating the efficacy of pregabalin alleviating spontaneous manifestations of neuropathic pain models in mice are lacking.Different clinical studies (Papazisis and Tzachanis, ; Bossard et al., ; Schjerning et al., ; Evoy et al., ) and individual reports (Filipetto et al.,
European Journal of Pain – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud